Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Maridebart, an antibody targeting GIPR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Fepixnebart, an antibody targeting EREG.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Iluzanebart, an antibody targeting TREM2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lomvastomig, an antibody targeting PD-1 × HAVCR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Devextinetug, an antibody targeting Metamphetamine.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Duvakitug, an antibody targeting TNFSF15.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Falbikitug, an antibody targeting LIF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Casdozokitug, an antibody targeting IL27.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dargistotug, an antibody targeting TIGIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Boserolimab, an antibody targeting TNFRSF7.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bempikibart, an antibody targeting IL-7R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Acimtamig, an antibody targeting CD16A × CD30.